Aerpio Pharmaceuticals Inc. revealed today that that company has signed a licensing agreement that could be worth more than $400 million.
The Blue Ash-based firm (OTCQB: ARPO) will be paid $20 million up front by GB004 Inc. for an Aerpio stabilizer in development to treat inflammatory bowel disease.
Click here to read the complete article. Story excerpt provided by Cincinnati Business Courier. Written by Barrett J. Brunsman. Originally published June 25, 2018.